RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

DNA Funded vs Monevis

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

DNAF
DNA Funded
Monevis
MNVS
Monevis
EST. 2023
DNA FUNDED
METRIC
MONEVIS
0/100—
TRUST SCORE
BETTER68/100
0/5TIE
RATING
TIE0/5
—
PROFIT SPLIT
85%
—
MAX FUNDING
$400,000
—
MIN COST
$49
—
PAYOUT DAYS
7d
—
PASS RATE
—
0TIE
REVIEW COUNT
TIE0

DNA FUNDED DETAILS

STEPS
-phase

MONEVIS DETAILS

STEPS
2-phase
DRAWDOWN
Fixed
MARKETS
Forex, Indices, Commodities, Metals
PLATFORMS
MT4, MT5
TYPES
forex

DNA Funded PROS

  • +No performance data is available to identify any above-average metrics for this firm
  • +No fee, payout, or structure data provided to evaluate competitiveness
  • +No platform or market data available to assess trading flexibility
  • +Country of operation (Australia) is noted, but no regulatory or structural data exists

DNA Funded CONS

  • −No data is provided for this firm, making any meaningful comparison impossible
  • −Traders cannot assess profit split, funding, or costs against the 84.7% and $186.7 averages
  • −Complete absence of data is a significant transparency concern for traders making financial decisions

Monevis PROS

  • +Profit split of 85% is above the industry average of 84.7%, giving traders a slightly better earnings share.
  • +Min challenge cost of $49 is well below the industry average of $186.7, making entry highly affordable.
  • +Weekend holding, news trading, and EA/automated trading are all permitted, supporting diverse trading approaches.
  • +On-demand payouts provide traders with maximum flexibility in withdrawing earned profits.

Monevis CONS

  • −Max funding of $400,000 is well below the industry average of $839,272.7, limiting overall earning potential.
  • −Overall drawdown of 8% slightly exceeds the industry average of 7.9%, offering marginally less buffer.
  • −Founded in 2023, Monevis has a limited track record, which may concern traders prioritising firm stability.

PROPDNA VERDICT

DNA Funded
Lower trust score (0/100). Slower payouts at —d.
Monevis
Higher trust score (68/100). Faster payouts at 7d. 85% profit split.

RELATED LINKS

DNA Funded Full Review →Monevis Full Review →All Comparisons →
← COMPARE ALL FIRMS ON PROPDNA

Affiliate disclosure: PropDNA may earn a commission if you start a challenge through links on this page. Scores are calculated algorithmically from verified trader reviews — not influenced by commercial relationships.Privacy Policy